美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

INVESCO BIOTECHNOLOGY & GENOME ETF

94.91

-0.7598-0.79%

盤後：94.910.00000.00%19:30 EDT

成交量：1.99萬

成交額：188.45萬

市值：4.12億

市盈率：52.93

高：95.59

開：95.59

低：94.69

收：95.67

52周最高：98.82

52周最低：67.69

股本：434.00萬

流通股本：434.00萬

量比：1.80

換手率：0.46%

股息：1.55

股息率：1.63%

每股收益(TTM):1.79

每股收益(LYR):18.65

淨資產收益率：24.76%

總資產收益率：0.08%

市淨率：1.67

市盈率(LYR):5.09

資料載入中...

總覽公司新聞資訊公告

Alnylam下調2026年產品銷售預期後股價下跌

阿爾尼拉姆製藥公司公布2026年第二季度財報，並重點回顧近期階段性進展

老藥衰退新藥接棒！收購驅動轉型初見成效，百健(BIIB.US)上調全年營收指引

AbCellera Biologics獲2800萬美元預付款及里程碑付款與階梯式版税

AbCellera攜手福泰製藥，共同開發針對自身免疫疾病的多特異性T細胞接合器

渤健公司：因整合Apellis，截至2026年6月30日止三個月及六個月確認1.532億美元税前重組淨支出

渤健公司：中東衝突未對2026年上半年經營業績產生實質性影響

渤健公司：預計2026年現行關税不會對業務產生重大不利影響

渤健公司：Ieepa關税退款最終回收金額或與此前全額支付存在差異

渤健：高劑量Spinraza轉換進度超預期，已覆蓋所有已上市地區

百健新藥推動增長，季度業績超出預期

安進(AMGN)股票7月28日盤中上漲4.02%：背後推手曝光

TradingKey中文

解讀世界500強排行榜醫藥板塊：強生繼續「霸榜」，禮來排名上升112位，3家中國企業入選

每日经济新闻

安進提交新數據，對美國食品藥品監督管理局（FDA）關於撤回Tavneos的提議提出異議

百濟神州/安進 FIC 雙抗，皮下製劑進入 III 期

創新藥研發加速遇「猴荒」

安進就股東提起的指控其隱瞞107億美元税單的訴訟達成和解

Royalty Pharma宣佈2026年第三季度股息派發

衞材：加拿大藥品管理機構認可Leqembi臨床價值，建議將早期阿爾茨海默病納入公共醫保覆蓋

a16z投資、百健CEO坐鎮！心血管新藥研發商Braveheart(BRVE.US)衝刺納斯達克IPO

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/PBE/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PBE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","market":"US","secType":"STK","nameCN":"INVESCO BIOTECHNOLOGY & GENOME ETF","latestPrice":94.91,"timestamp":1789761600000,"preClose":95.6698,"halted":0,"volume":19855,"hourTrading":{"tag":"盘后","latestPrice":94.91,"preClose":94.91,"latestTime":"19:30 EDT","volume":11,"amount":1042.81,"timestamp":1789774205884,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007941900160761269,"floatShares":4340000,"shares":4340000,"eps":1.793292,"marketStatus":"休市中","change":-0.7598,"latestTime":"09-18 16:00:00 EDT","open":95.59,"high":95.59,"low":94.69,"amount":1884465.847,"amplitude":0.009407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.793292,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":95.6698,"sharesOutstanding":3180000,"nav":95.66478,"aum":414120917.85,"dividendRate":0.01633,"bidAskSpread":0.002296,"preHourTrading":{"tag":"盘前","latestPrice":93.38,"preClose":95.6698,"latestTime":"07:13 EDT","volume":5,"amount":466.9,"timestamp":1789730023426,"change":-2.2898,"changeRate":-0.023934,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":94.91,"preClose":94.91,"latestTime":"19:30 EDT","volume":11,"amount":1042.81,"timestamp":1789774205884,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.8031312986512782,"impliedVol":0.1158,"impliedVolPercentile":0.0398},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","floatShares":4340000,"roa":"0.08%","roe":"24.76%","lyrEps":18.654418,"volumeRatio":1.8031312986512782,"shares":4340000,"dividePrice":1.5499,"high":95.59,"amplitude":0.009407,"preClose":95.6698,"low":94.69,"week52Low":67.69,"pbRate":"1.67","psRate":"239.95","week52High":98.82,"institutionHeld":0.2552,"latestPrice":94.91,"eps":1.793292,"divideRate":0.01633,"volume":19855,"delay":0,"ttmEps":1.793292,"open":95.59,"prevYearClose":82.15,"prevWeekClose":92.91,"prevMonthClose":96.68,"prevQuarterClose":89.6486,"fiveDayClose":92.91,"twentyDayClose":96.56,"sixtyDayClose":87.3983},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBE\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"PBE","amount":0.01867,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"PBE","amount":0.81061,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"PBE","amount":0.08244,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"PBE","amount":0.41972,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"PBE","amount":0.23409,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBE\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.1208,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-31","value":0.05552,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-30","value":0.21532,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00207,"currency":"USD"},{"executeDate":"2020-03-23","recordDate":"2020-03-24","paymentDate":"2020-03-31","value":0.02898,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBE\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655773978","title":"Alnylam下調2026年產品銷售預期後股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2655773978","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655773978?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 20:24","pubTimestamp":1785414259,"startTime":"0","endTime":"0","summary":"BUZZ-Alnylam下调2026年产品销售预期后股价下跌7月30日-** 制药公司Alnylam Pharmaceuticals（ALNY.O）的股价在盘前交易中下跌21.5%，至225.00美元** 该公司将2026年产品总净收入预期从此前预估的49亿至53亿美元下调至47亿至51亿美元** 第二季度销售额为1.29亿美元，低于分析师预期的1.32亿美元——据伦敦证券交易所集团（LSEG）数据** 报告显示第二季度调整后每股收益为1.84美元，高于1.55美元的预期** 截至上一交易日收盘，该股年内累计跌幅达27.9%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL4S43W1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0114720955.EUR","ALNY","BK4585","GNMX","BK4588","LU0320765992.SGD","BK4139","LU0109394709.USD","BK4548","LU0889565916.HKD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175560090","title":"阿爾尼拉姆製藥公司公布2026年第二季度財報，並重點回顧近期階段性進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1175560090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175560090?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 20:02","pubTimestamp":1785412965,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司于近日正式披露了2026年第二季度的财务业绩。与此同时，该公司还着重梳理了在过去一段时间内所取得的各项关键进展。在回顾近期发展时，阿尔尼拉姆强调，其针对多项罕见病及常见疾病的RNAi疗法研究已进入新的里程碑阶段。总体而言，这段时期标志着阿尔尼拉姆在科学探索与商业价值实现上均迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","PBE","BK4588","LU0320765992.SGD","ALNY","BK4585","LU0882574055.USD","LU0109394709.USD","LU0114720955.EUR","GNMX","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655606328","title":"老藥衰退新藥接棒！收購驅動轉型初見成效，百健(BIIB.US)上調全年營收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2655606328","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655606328?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 20:10","pubTimestamp":1785327014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B19Z9P08.USD","BK4585","BMED","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4588","LU0234570918.USD","BK4533","PBE","BK4532","LU0320765992.SGD","LU0109394709.USD","BIIB","BK4139","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics獲2800萬美元預付款及里程碑付款與階梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185330982?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","SGXZ57979304.SGD","SG9999001176.SGD","GNMX","IE00B4R5TH58.HKD","IE00B19Z3B42.SGD","IE00BFTCPJ56.SGD","LU1674673428.USD","ABCL","IE00B19Z9Z06.USD","LU0432979614.USD","IE00B894F039.SGD","LU0823416689.USD","LU0320765992.SGD","LU1035775433.USD","IE0002270589.USD","LU0889565916.HKD","LU1778281490.HKD","BK4139","BK4533","LU0061475181.USD","BIB","LU0109394709.USD","IE00B19Z9P08.USD","IBBQ","LU1093756325.SGD","BK4567","IE00BJJMRZ35.SGD","LU2236285917.USD","LU0058720904.USD","LU2362541273.HKD","IE00BZ9MQY76.HKD","SG9999013999.USD","TBXU","BK4535","IE0002141913.USD","LU0289739699.SGD","LU2237438978.USD","LU2417539215.USD","IE00BJT1NW94.SGD","BK4532","LU2362541513.USD","VRTX","LU0079474960.USD","LU2456880835.USD","LU0234570918.USD","IE00B19Z3581.USD","IE00B2B36J28.USD","LU2324357040.USD","BK4121","LU0417517546.SGD","BBH","BK4585","LU0256863811.USD","LU1430594728.SGD","LU1069344957.HKD","LU1585245621.USD","BK4588","LU2362540622.SGD","LU2462157665.USD","SG9999001176.USD","LU1093756168.USD","LU1674673691.USD","PBE","IE0009355771.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera攜手福泰製藥，共同開發針對自身免疫疾病的多特異性T細胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147206442?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作，旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势，致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","SG9999013999.USD","BK4121","TBXU","LU1778281490.HKD","LU2324357040.USD","LU2462157665.USD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU2362540622.SGD","LU2417539215.USD","BK4588","IBBQ","IE00B19Z3B42.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU2362541273.HKD","BIB","IE00B19Z9Z06.USD","LU0109394709.USD","PBE","BK4139","IE00B4R5TH58.HKD","LU0061475181.USD","LU0256863811.USD","IDNA","LU0320765992.SGD","LU2236285917.USD","SGXZ57979304.SGD","LU0823416689.USD","LU0079474960.USD","IE0002270589.USD","LU1069344957.HKD","IE0009355771.USD","LU0417517546.SGD","LU1674673428.USD","GNMX","LU1430594728.SGD","IE00BZ9MQY76.HKD","LU2362541513.USD","IE00B894F039.SGD","LU1093756168.USD","LU0432979614.USD","BK4532","SG9999001176.SGD","VRTX","IE00B19Z3581.USD","BK4535","BK4533","IE00B2B36J28.USD","SG9999001176.USD","LU1035775433.USD","BBH","BK4567","LU1093756325.SGD","LU2456880835.USD","IBB","IE00BJT1NW94.SGD","LU0289739699.SGD","IE0002141913.USD","LU1674673691.USD","LU2237438978.USD","IE00B19Z9P08.USD","LU1585245621.USD","ABCL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173868024","title":"渤健公司：因整合Apellis，截至2026年6月30日止三個月及六個月確認1.532億美元税前重組淨支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1173868024","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173868024?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:46","pubTimestamp":1785321986,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）披露，为推进与Apellis的整合进程，在截至2026年6月30日的三个月及六个月期间内，公司确认了高达1.532亿美元的净税前重组费用。这笔支出旨在优化资源配置，加速业务融合，并应对市场结构性变化。重组举措覆盖了运营调整、人员精简及资产处置等多个方面，以提升长期竞争力。具体而言，这些费用主要源于整合相关活动，包括关闭重叠设施、削减冗余岗位以及处理遗留合同等。公司方面强调，尽管短期面临财务压力，但此举是实现战略协同、释放合并后价值的关键步骤。未来，渤健将继续评估整合进度，并适时调整财务预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BMED","LU0109394709.USD","LU0320765992.SGD","PBE","LU0889565916.HKD","BK4533","LU0234570918.USD","BK4588","IE00B19Z9Z06.USD","BK4532","IE00B19Z9P08.USD","BK4585","BIIB","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147971918","title":"渤健公司：中東衝突未對2026年上半年經營業績產生實質性影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1147971918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147971918?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:43","pubTimestamp":1785321809,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）最新披露，中东地区的地缘冲突局势，并未对其截至2026年6月30日的三个月及六个月期间的经营业绩，构成任何实质性影响。这一表态，清晰地向市场传递了其业务在外部动荡环境下的韧性。从短期业绩到中期财务状况，这家生物科技巨头均未因该地区的不确定性而遭受显著冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","BIIB","BK4139","BK4588","LU0109394709.USD","LU0889565916.HKD","LU0234570918.USD","IE00B19Z9P08.USD","PBE","BK4585","BK4533","LU0320765992.SGD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112467763","title":"渤健公司：預計2026年現行關税不會對業務產生重大不利影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1112467763","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112467763?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:42","pubTimestamp":1785321735,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）在最新提交的文件中明确指出，其当前业务所面临的关税政策，预计不会在2026年对公司的运营造成实质性负面冲击。这一表态，为市场吃下了一颗定心丸。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4532","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BMED","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BIIB","PBE","LU0234570918.USD","BK4139","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130360697","title":"渤健公司：Ieepa關税退款最終回收金額或與此前全額支付存在差異","url":"https://stock-news.laohu8.com/highlight/detail?id=1130360697","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130360697?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:42","pubTimestamp":1785321729,"startTime":"0","endTime":"0","summary":"渤健公司表示，其最终可能获得的Ieepa关税退款（如有）金额，或将与此前全部支付款项有所不同。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BIIB","IE00B19Z9P08.USD","IE00B894F039.SGD","PBE","LU0234570918.USD","BK4585","LU0889565916.HKD","BK4532","BMED","LU0320765992.SGD","BK4139","BK4588","IE00B19Z9Z06.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138863286","title":"渤健：高劑量Spinraza轉換進度超預期，已覆蓋所有已上市地區","url":"https://stock-news.laohu8.com/highlight/detail?id=1138863286","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138863286?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:02","pubTimestamp":1785319323,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）宣布，其高剂量Spinraza治疗方案在已上市的所有地理区域中，转换进度均超出公司预期。这一进展表明，患者对该剂型的接受度与医疗系统的适应速度均优于先前的规划。渤健表示，高剂量方案的推广正按计划稳步推进，且在某些市场甚至提前实现了预设目标。这一趋势反映出公司对神经肌肉疾病治疗的持续优化能力，以及市场对创新疗法的积极反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4532","IE00B19Z9P08.USD","BK4585","IE00B19Z9Z06.USD","BK4588","IE00B894F039.SGD","BMED","BIIB","LU0889565916.HKD","LU0234570918.USD","BK4139","BK4533","PBE","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655866889","title":"百健新藥推動增長，季度業績超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655866889","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655866889?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 18:01","pubTimestamp":1785319260,"startTime":"0","endTime":"0","summary":"百健新药推动增长，季度业绩超出预期路透7月29日-百健BIIB.O周三公布的第二季度利润和营收均超出华尔街预期，这主要得益于其罕见病药物的强劲需求，而其传统多发性硬化症药物的销售则仍面临压力。百健与卫材4523.T联合开发的阿尔茨海默病药物Leqembi，其全球销售额较上年增长15%，达到约1.84亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4T43V0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4533","LU0320765992.SGD","PBE","IE00B19Z9P08.USD","BK4532","IE00B894F039.SGD","LU0234570918.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","BMED","BK4588","BIIB","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884494","title":"安進(AMGN)股票7月28日盤中上漲4.02%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884494","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655884494?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 02:16","pubTimestamp":1785262601,"startTime":"0","endTime":"0","summary":"• 安进第二季度业绩超预期，并上调了全年业绩指引。\n• 减肥药 MariTide 的积极临床数据推动了股价上涨。\n• 包括 MACD 和 Williams %R 在内的技术指标提示当前为买入信号。","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262059433-market-movers-amgn-20260728","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4534","BK4588","LU2468319806.SGD","LU0109394709.USD","IE0002141913.USD","PJP","IE00B2B36J28.USD","LU0122379950.USD","LU2242646821.SGD","TBXU","LU1057294990.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1023059063.AUD","AMGN","LU0058720904.USD","IBB","LU2242652126.USD","PBE","LU2112291526.USD","IBBQ","BK4599","BK4566","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","BBH","LU0289739699.SGD","LU0320765992.SGD","LU1061106388.HKD","BK4581","LU1983299246.USD","SG9999001440.SGD","BK4533","LU0889565916.HKD","IE00B4R5TH58.HKD","BIB","BK4139","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007935","title":"解讀世界500強排行榜醫藥板塊：強生繼續「霸榜」，禮來排名上升112位，3家中國企業入選","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007935","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007935?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 20:51","pubTimestamp":1785243108,"startTime":"0","endTime":"0","summary":"7月28日，2026年《财富》世界500强榜单正式发布。《每日经济新闻》记者注意到，医疗健康板块作为全球五大支柱行业之一，共有31家企业上榜。其中，礼来公司排名从2025年的336位上升至今年的224位，成为今年上涨最快的10家公司之一。中国公司中，中国医药集团、上海医药、广药集团3家公司再次入围。《每日经济新闻》记者注意到，位居医疗健康相关企业榜首的是联合健康集团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823749452.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823749452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU0289961442.SGD","LU0795875086.SGD","LU0861579265.USD","LU0708995401.HKD","SG9999014880.SGD","LU2108987350.USD","LU1061106388.HKD","LU0289739699.SGD","LU2362540622.SGD","LU1496350502.SGD","LU2237438978.USD","IE00B19Z9Z06.USD","SG9999014559.SGD","SG9999001440.SGD","LU2023250504.SGD","LU1551013425.SGD","LU1127390331.HKD","IE00BK4W5M84.HKD","LU1291159041.SGD","TRUH","LU0354030438.USD","LU0256863811.USD","LU1032466523.USD","IE00B19Z8X17.USD","LU1232071149.USD","LU2023251221.USD","LU2360032135.SGD","LU1732800096.USD","LU1244550221.USD","BK4139","BK4581","LU2462591277.SGD","LU2028103732.USD","LU1571399168.USD","LU0211326839.USD","LU1883839398.USD","LU2237443549.SGD","IE00BJJMRZ35.SGD","LU2746668461.USD","LU0143551892.USD","LU2087625088.SGD","LU0466842654.USD","LU2471134796.USD","LU1983299246.USD","IE00BJJMRX11.SGD","LU0077335932.USD","LU2750360641.GBP","GB00BDT5M118.USD","LU0211331839.USD","LU0158827948.USD","SG9999015341.SGD","LU2324357040.USD","IE00BFSS7M15.SGD","LU1732799900.SGD","BK4154","UNHU","BK4516","LU2456880835.USD","LU1854104046.USD","LU0316494557.USD","LU0320765646.SGD","LU2487616109.SGD","FTXH","LU0823434583.USD","LU0882574139.USD","LU2106854487.HKD","LU1057294990.SGD","LU1043141396.HKD","LU2471134879.HKD","BK4588","IE00BFXG1179.USD","LU0238689110.USD","LU2592432038.USD","SGXZ81514606.USD","JDOC","LU1084165304.USD","LU0965509283.SGD","LU1323610961.USD","LU0823416689.USD","LU1032955483.USD","HRTS","LU2125154778.USD","LU2552382215.SGD","LU1989772923.USD","IE0004445239.USD","LU0320765489.SGD","LU0225284248.USD","LU0557290698.USD","LU0994945656.USD","LU2237443895.HKD","LU0820562030.AUD","LU0052756011.USD","IE00BSNM7G36.USD","LU1941712348.USD","SG9999014906.USD","ABBV","LU0545562505.USD","LU2133065610.SGD","LU0320765992.SGD","LU0124676726.USD","LU1201861249.SGD","PAWZ","IE0004445015.USD","LU0964807845.USD","LU2462157665.USD","IE00BLSP4239.USD","LU2552382058.USD","AMGN","LU0211327993.USD","LU1066051498.USD","LU2237443382.USD","LU1119994496.HKD","LU1548497426.USD","LU1791710582.SGD","MHIP","LU0868494708.USD","IE00BDGV0183.EUR","IE0005OL40V9.USD","IE00BJJMRY28.SGD","LU2023250843.SGD","LU0109391861.USD","LU1003077747.HKD","LU1712237335.SGD","LU2125909247.SGD","BIB","LU1035773651.USD","LU0122379950.USD","BK4559","MEDX","LU1162221912.USD","LU1868837300.USD","LU0965509101.SGD","LU0211326755.USD","CANC","LU0949170772.SGD","IE00B4R5TH58.HKD","LU1064131342.USD","LU1221951129.SGD","LU1623119135.USD","LU2213496289.HKD","VHT","SG9999011175.SGD","LU0889565916.HKD","SG9999001176.SGD","IE00B3T34201.USD","SG9999001176.USD","LU0726765562.USD","LU1923622614.USD","LU0048584097.USD","LU0198837287.USD","LU1551013342.USD","LU2236285917.USD","LU0187121727.USD","LU0265550359.USD","LU2357305700.SGD","LU0980610538.SGD","IE00B19Z9505.USD","IE00BBT3K403.USD","LU0149725797.USD","SG9999018865.SGD","LU1267930573.SGD","THNR","LU1934455194.USD","NVOH","LU1988902786.USD","LU0471298694.HKD","IE00B19Z3581.USD","LLYX","LU1261432733.SGD","LU2361045086.USD","LU0306807586.USD","RXL","IHF","LU0053666078.USD","LU1267930227.SGD","LU2237443465.HKD","LU1674673691.USD","BK4007","LU1974910355.USD","TBXU","LU1718418525.SGD","LU2129689605.HKD","SG9999015986.USD","SGXZ51526630.SGD","IE00B7KXQ091.USD","LU2271345857.HKD","LU0210528500.USD","LU0320765059.SGD","LU0210536198.USD","PJP","LU1267930813.SGD","AGNG","SG9999015952.SGD","SG9999014914.USD","LU0496365809.HKD","LU0345770993.USD","LU2242649171.HKD","LU0820561909.HKD","LU0321505868.SGD","SGXZ57979304.SGD","LU0289739343.SGD","LU1035775433.USD","LU1804176565.USD","BMED","LU0211328371.USD","LU1228905540.USD","LU2505996509.AUD","LU2242652126.USD","IE00BVYPNW00.USD","LU0985320562.USD","LU0128525929.USD","LU0426417589.USD","LU0203345920.USD","IE00BWXC8680.SGD","BK4578","LU0061475181.USD","LU0234572021.USD","LU1934455277.USD","LLY","LU0738911758.USD","LU2168564065.EUR","SG9999013999.USD","XLV","LU0661504455.SGD","LU2430703095.HKD","SG9999015978.USD","IE000SO60NU8.SGD","LU0456855351.SGD","LU2750360997.AUD","LU0426412945.USD","IE0034235303.USD","LU0345769631.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU2433249047.HKD","LU0345769128.USD","LU0912757837.SGD","LU1267930490.SGD","LU0006306889.USD","LU2362541273.HKD","LU0234570918.USD","LU0823434740.USD","LU1228905037.USD","LU0354030511.USD","LU2168564149.EUR","IE00BJT1NW94.SGD","SG9999017495.SGD","NVS","LU0310800379.SGD","LU2089283258.USD","LU0471298777.SGD","LU0976567544.SGD","IE00BN8TJ469.HKD","LU0648001328.SGD","LU1917777945.USD","LU2264538146.SGD","LU0477156953.USD","LU2360106947.USD","SG9999014567.USD","LU0162691827.USD","LU0203201768.USD","LU1366192091.USD","LU2129689514.USD","LU2491050071.SGD","IE00B2B36J28.USD","LU2361044949.HKD","LU2403377893.USD","LU2125154935.USD","LU2023250330.USD","LU1720051108.HKD","LU1629891620.HKD","UNHW","LU0859254822.USD","LU1496350171.SGD","RHHBY","LU0689626769.HKD","LU0203202063.USD","WDNA","LU2756315664.SGD","IE00B1XK9C88.USD","LU0107464264.USD","BK4534","IE0002270589.USD","LU1868836914.USD","SG9999018857.SGD","IE0002141913.USD","LU2417539215.USD","LU1093756168.USD","LU2129689431.USD","LU0130102774.USD","IE00BFTCPJ56.SGD","LU0787776722.HKD","IXJ","LU0079474960.USD","LU0011850046.USD","LU2461242641.AUD","LU2552382132.HKD","LU2347655156.SGD","LLII","LU1506573853.SGD","LU0058720904.USD","LU0965508806.USD","LU2168563687.JPY","GDOC","LU0689472784.USD","UNHG","IE00B4JS1V06.HKD","LU1074936037.SGD","NVO","LU1145028129.USD","IE00B894F039.SGD","FHLC","LU0266013472.USD","LU0154236417.USD","IE00BKDWB100.SGD","IYH","LU2471134952.CNY","LU0208291251.USD","LU2357627491.SGD","LU0417517546.SGD","SG9999015945.SGD","LU0882574055.USD","LU1778281490.HKD","NVOX","LU0672654240.SGD","IE00BKPKM429.USD","UNH","LU1839511570.USD","LU0345770308.USD","LU0256863902.USD","LU2063271972.USD","LU0096364046.USD","LU0158827781.USD","IE00BZ1G4Q59.USD","LU0395794307.EUR","LU1043141123.HKD","LU1941712264.USD","IE00B19Z9P08.USD","IE00BVYPNV92.GBP","ELIS","LU0094547139.USD","LU0106261372.USD","LU2756315318.SGD","LU0321505439.SGD","LU0792757196.USD","LU1720051017.SGD","LU1894683348.USD","LU0889566641.SGD","LU1059921491.USD","CURE","LU0786609619.USD","LU0820561818.USD","LU1935042991.SGD","IE0009355771.USD","LU0072461881.USD","LU1244550494.USD","LU0306806265.USD","LU2242646821.SGD","LU0942090050.USD","IE00BZ9MQY76.HKD","LU0342679015.USD","BK4504","IHE","IE00BJLML261.HKD","BK4532","LU2211815571.USD","LU0640476718.USD","IE0000B7K699.USD","LU1116320901.HKD","LU0265550946.USD","LU2430703251.USD","LU2471134523.USD","LU1037948897.HKD","LU2602419157.SGD","LU1069347547.HKD","LU0323591593.USD","LU2999663052.SGD","LU0029864427.USD","LU1093756325.SGD","LU0353189763.USD","LU0511384066.AUD","LU0070302665.USD","LU2954938101.SGD","LU0683600562.USD","IE00B19Z8W00.USD","LU0130517989.USD","LU0708994859.HKD","BK4533","IE00B42XCP33.USD","LU2362541513.USD","LU1989772840.SGD","LU0432979614.USD","IE00B3PB1722.GBP","LU2089984988.USD","LU0472753341.HKD","TMED","LU0070217475.USD","LU2361044865.SGD","LU1814569148.SGD","SG9999003800.SGD","LU1894683264.USD","GLAM","JNJ","LU0133085943.USD","LU0251132253.USD","SG9999014542.SGD","IE000MB6IJN5.SGD","IE00BK4W5L77.USD","IE00BGHQF631.EUR","LU0943347566.SGD","IE0001KFT4U8.USD","IE000M9KFDE8.USD","LU0353189680.USD","LU2746668974.SGD","LU2244417387.USD","IBB","LU1280957306.USD","SG9999014898.SGD","LU2237443622.USD","LU0170899867.USD","MRK","LU2087621335.USD","SG9999015358.SGD","ELIL","LU2462591350.SGD","LU2279689827.SGD","LU2430703178.SGD","04332","LU2468319806.SGD","LU0528227936.USD","LU0545039389.USD","LU2168564495.EUR","OZEM","LU1221951046.USD","LU2111349929.HKD","PPH","LU2237443978.SGD","LU0965509010.AUD","LU0128525689.USD","LU0795875169.SGD","LU1430594728.SGD","LU2491050154.USD","IE00BFSS8Q28.SGD","PFE","LU1196500208.SGD","LU1868836757.USD","LU0203347892.USD","LU2596442595.SGD","IE00BN29S564.USD","PBE","LU1670628061.USD","LU2089284900.SGD","BK4566","LU2347655073.USD","LU2265009873.SGD","LU0114720955.EUR","LU0174119429.USD","LU1023059063.AUD","BK4550","LU2168564222.USD","LU1699723380.USD","LU0098860793.USD","LU0310799852.SGD","LU0310800965.SGD","LU1244550577.SGD","BK4599","LU1066051811.HKD","SGXZ31699556.SGD","SG9999002232.USD","IE000WAW04H5.SGD","LU1267930730.SGD","IE00BKVL7J92.USD","LU0097036916.USD","LU0069063385.USD","LU0553294199.USD","IE000BZT7R73.USD","LU1929549753.HKD","LU1670627923.USD","LU1934455863.HKD","IE000F7OJYX1.SGD","LU1989771016.USD","BK4592","LU2112291526.USD","LU1121112475.USD","SG9999014575.USD","LU1066051225.USD","03165","LU1037948541.HKD","LU0985481810.HKD","MEDI","LU2505996681.GBP","IE00B7SZLL34.SGD","LU0057025933.USD","LU0225771236.USD","LU0385154629.USD","LU2125909593.SGD","LU1116320737.USD","LU1674673428.USD","BK4568","IE00B775H168.HKD","LU1791710400.SGD","IE00BLSP4452.SGD","LU0109394709.USD","LU1069344957.HKD","LU2491049909.HKD","LU1868836591.USD","SG9999002224.SGD","LU0868494617.USD","LU1914381329.SGD","SGXZ99366536.SGD","BBH","IE00B1BXHZ80.USD","LU1153585028.USD","ILDR","LU1868837136.USD","LU2896262040.SGD","LU1585245621.USD","LU1854103824.USD","IBBQ","LLYZ","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653080634","title":"安進提交新數據，對美國食品藥品監督管理局（FDA）關於撤回Tavneos的提議提出異議","url":"https://stock-news.laohu8.com/highlight/detail?id=2653080634","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653080634?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 21:44","pubTimestamp":1784900670,"startTime":"0","endTime":"0","summary":"安进提交新数据，对美国食品药品监督管理局关于撤回Tavneos的提议提出异议路透7月24日-安进公司周五表示，该公司已于7月23日向美国食品药品监督管理局提交了新证据，以寻求举行听证会，对该公司的罕见病药物Tavneos拟从美国市场撤回的决定提出异议。美国食品药品监督管理局未立即回应路透的置评请求。美国食品药品监督管理局今年4月表示，除非安进公司主动撤回该药，或FDA局长下令撤回，否则Tavneos将继续在美国市场销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4T43Q16X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","BBH","BK4599","PJP","IE00B2B36J28.USD","IE0002141913.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU0868494617.USD","LU0122379950.USD","BK4139","LU1023059063.AUD","PBE","IE0009355771.USD","BIB","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4581","LU1983299246.USD","LU2242646821.SGD","LU2112291526.USD","IBB","LU0109394709.USD","LU0058720904.USD","AMGN","BK4588","IBBQ","IE00BFTCPJ56.SGD","BK4533","IE00BJT1NW94.SGD","LU1057294990.SGD","LU0320765992.SGD","LU0889565916.HKD","LU0289739699.SGD","TBXU","BK4566","BK4585","LU2242652126.USD","LU1571399168.USD","BK4534","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074709","title":"百濟神州/安進 FIC 雙抗，皮下製劑進入 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074709","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653074709?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":"7 月 22 日，药物临床试验登记与信息公示平台显示，安进和百济神州共同登记了一项在接受含铂一线化疗后的复发性广泛期小细胞肺癌试验参与者中比较 Tarlatamab皮下给药与静脉给药的 III 期研究DeLLphi-315。在皮下剂型的开发方面，安进和百济神州于 2024 年 9 月启动了一项在广泛期小细胞肺癌受试者中评价 Tarlatamab 皮下给药的安全性、耐受性、药代动力学和初步抗肿瘤活性的 Ib 期研究 DeLLphi-308。而本次启动的DeLLphi-315 研究是塔拉妥单抗皮下给药方案启动的首个 III 期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-23/doc-iniivazc5268721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0889565916.HKD","06160","LU2468319806.SGD","LU1061106388.HKD","BK4581","PBE","BK4134","TBXU","BK1500","BK1588","LU0320765992.SGD","LU1719994722.HKD","IE0002141913.USD","LU2242646821.SGD","IBBQ","IBB","BK4139","AMGN","LU0289739699.SGD","SG9999001440.SGD","LU2242652126.USD","BK4534","BK4599","LU1969619763.USD","LU0868494617.USD","BK1583","PJP","KURE","LU1251922891.USD","BK4585","IE0009355771.USD","IE00B4R5TH58.HKD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU2328871848.SGD","LU1770034418.SGD","III","BIB","LU0588546209.SGD","LU0058720904.USD","LU1571399168.USD","ONC","688235","LU1303224171.USD","LU0122379950.USD","IE00BJT1NW94.SGD","LU0307460666.USD","BK4588","BBH","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"創新藥研發加速遇「猴荒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","BK4588","WRND","GDOC","BBP","BK4585","XLVI","SBIO","GSKH","LFSC","PBE","BIOY","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653206285","title":"安進就股東提起的指控其隱瞞107億美元税單的訴訟達成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2653206285","media":"路透中文","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653206285?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 23:07","pubTimestamp":1784646437,"startTime":"0","endTime":"0","summary":"安进就股东提起的指控其隐瞒107亿美元税单的诉讼达成和解Jonathan Stempel路透纽约7月21日-安进公司就一起指控其延迟披露可能因六年税款申报不足而需向美国国税局补缴107亿美元的诉讼，达成了一项7400万美元的和解协议。安进否认有任何不当行为，并于周二表示仍认为这些指控毫无依据。美国国税局就安进公司所谓的“转让定价”做法，要求其补缴87亿美元税款及利息，并处以20亿美元罚款。安进公司表示，美国税务法院的裁决可能于今年作出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL4T43N1GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BIB","LU0058720904.USD","LU1061106388.HKD","BK4533","BK4139","IBB","TBXU","BBH","BK4581","LU2089984988.USD","IE0009355771.USD","LU2468319806.SGD","LU2112291526.USD","LU0109394709.USD","PJP","BK4599","LU0889565916.HKD","LU0320765992.SGD","LU0289739699.SGD","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU2242646821.SGD","IE00BJT1NW94.SGD","BK4566","LU0868494617.USD","IBBQ","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU1571399168.USD","LU0122379950.USD","LU1057294990.SGD","PBE","BK4588","AMGN","LU1023059063.AUD","LU1983299246.USD","LU2242652126.USD","IE00B4R5TH58.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129561583","title":"Royalty Pharma宣佈2026年第三季度股息派發","url":"https://stock-news.laohu8.com/highlight/detail?id=1129561583","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129561583?lang=zh_tw&edition=fundamental","pubTime":"2026-07-18 04:17","pubTimestamp":1784319458,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc董事会已批准派发2026年第三季度股息，每股A类普通股股息为0.235美元。此次股息将于2026年9月10日支付给截至2026年8月14日营业结束时登记在册的股东。Royalty Pharma成立于1996年，是生物制药领域特许权使用费的最大收购方，也是行业创新的重要资助者。Royalty Pharma构建了一个多元化的特许权组合，使其有权直接基于行业众多领先疗法的总销售额获得收益支付。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","RPRX","BK4007","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169524809","title":"衞材：加拿大藥品管理機構認可Leqembi臨床價值，建議將早期阿爾茨海默病納入公共醫保覆蓋","url":"https://stock-news.laohu8.com/highlight/detail?id=1169524809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169524809?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 20:17","pubTimestamp":1784204253,"startTime":"0","endTime":"0","summary":"加拿大药品管理机构已正式认可Leqembi的临床价值，并建议将其纳入公共医保覆盖范围，用于治疗早期阿尔茨海默病。这一积极建议标志着该创新疗法在获得更广泛患者可及性的道路上迈出了关键一步。Leqembi由卫材与渤健公司共同开发，是一种针对阿尔茨海默病潜在病理机制的靶向疗法。加拿大相关机构的认可，是基于其临床试验所展现出的减缓疾病进展的明确证据。此举若最终获得采纳，将显著减轻早期阿尔茨海默病患者及其家庭的经济负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4533","LU0320765992.SGD","LU0889565916.HKD","PBE","BMED","BK4139","BK4532","BK4588","BK4585","IE00B19Z9P08.USD","LU0109394709.USD","IE00B19Z9Z06.USD","BIIB","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946677","title":"a16z投資、百健CEO坐鎮！心血管新藥研發商Braveheart(BRVE.US)衝刺納斯達克IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946677","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651946677?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 21:35","pubTimestamp":1784122530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由 A16z 支持的临床阶段生物制药公司 Braveheart Bio Inc. 于周三向纳斯达克提交了 IPO 申请。这家心血管疾病药物开发商将寻求通过在纳斯达克全球市场销售股份来募集一笔尚未公布具体金额的资金。百健首席执行官克里斯托弗·维巴赫担任 Braveheart 的董事长。Braveheart 报告称，在 2026 年前三个月，其净亏损为 1430 万美元，并创造了约 1100 万美元的收入。相比之下，去年同期的前三个月净亏损为 9.9 万美元。Braveheart 将以股票代码“BRVE”进行交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4532","IE00B19Z9P08.USD","BK4585","IE00B19Z9Z06.USD","BK4588","IE00B894F039.SGD","BMED","BIIB","LU0889565916.HKD","LU0234570918.USD","BK4139","BK4533","PBE","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":152,"code":"91000000","status":"200"}]}}